TuisALTME • EPA
add
TME Pharma NV
Vorige sluiting
€0,086
Dagwisseling
€0,082 - €0,084
Jaarwisseling
€0,060 - €0,23
Markkapitalisasie
7,88 m EUR
Gemiddelde volume
1,04 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
EPA
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 9,50 k | 11,76% |
Bedryfskoste | 1,27 m | -12,11% |
Netto inkomste | -1,24 m | 19,60% |
Netto winsgrens | — | — |
Wins per aandeel | — | — |
EBITDA | -1,26 m | 12,07% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 3,24 m | 44,54% |
Totale bates | 3,41 m | 36,73% |
Totale aanspreeklikheid | 1,79 m | -35,66% |
Totale ekwiteit | 1,61 m | — |
Uitstaande aandele | 94,11 m | — |
Prys om te bespreek | 4,28 | — |
Opbrengs op bates | -92,52% | — |
Opbrengs op kapitaal | — | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -1,24 m | 19,60% |
Kontant van bedrywe | -949,50 k | 15,26% |
Kontant van beleggings | -6,50 k | — |
Kontant van finansiering | 1,23 m | 66,53% |
Netto kontantverandering | 268,50 k | 170,38% |
Beskikbare kontantvloei | -738,62 k | 3,49% |
Meer oor
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Gestig
1997
Webwerf
Werknemers
12
